Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its bioengineered vascular products.
On the company’s earnings call, President and Chief Executive Officer Dr. Laura Niklason said Humacyte’s main goals for 2026 include expanding the U.S. and global commercial launch of Symvess, completing the V012 Phase III pivotal trial of its acellular tissue engineered vessel, or ATEV, in dialysis access, filing a supplemental biologics license application with the U.S. Food and Drug Administration for the dialysis indication, and beginning a human study of its coronary tissue engineered vessel, or CTEV, in coronary artery bypass grafting.
